Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving Average - Time to Sell?

Key Points

• Technical signal: Shares of Corbus Pharmaceuticals (CRBP) crossed above their 50-day moving average ($8.41) on Tuesday, trading as high as $8.50 and last at $8.18, while the 200-day MA sits at $10.49.
• Analyst and valuation split: Ratings are mixed—Oppenheimer raised its target to $57 (outperform) while the consensus is a "Moderate Buy" with a $43.71 target—yet the company is small-cap ($145.11M) with negative profitability (PE -1.37) and an expected -4.23 EPS for the year.
• Clinical progress and ownership: Corbus's lead drug, lenabasum, is in a Phase 3 trial for diffuse cutaneous systemic sclerosis and other studies, and institutional investors now own about 64.64% of the stock after sizable position increases by several funds.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $8.41 and traded as high as $8.50. Corbus Pharmaceuticals shares last traded at $8.18, with a volume of 120,634 shares traded.

Analysts Set New Price Targets

CRBP has been the subject of several research reports. Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, March 10th. Jefferies Financial Group raised shares of Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.71.

Corbus Pharmaceuticals Price Performance

The company has a market capitalization of $145.11 million, a PE ratio of -1.37 and a beta of 2.84. The business's 50 day simple moving average is $8.41 and its 200 day simple moving average is $10.49.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.53. As a group, analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 EPS for the current year.

Insider Buying and Selling at Corbus Pharmaceuticals

In other news, insider Dominic Smethurst sold 3,285 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total transaction of $26,575.65. Following the completion of the transaction, the insider directly owned 95,887 shares in the company, valued at approximately $775,725.83. This represents a 3.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.00% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Aberdeen Group plc increased its position in shares of Corbus Pharmaceuticals by 602.2% during the fourth quarter. Aberdeen Group plc now owns 1,321,750 shares of the biopharmaceutical company's stock valued at $10,759,000 after acquiring an additional 1,133,519 shares during the last quarter. Orbimed Advisors LLC lifted its holdings in shares of Corbus Pharmaceuticals by 36.3% in the 4th quarter. Orbimed Advisors LLC now owns 1,597,287 shares of the biopharmaceutical company's stock worth $13,002,000 after acquiring an additional 425,000 shares during the last quarter. Armistice Capital LLC boosted its position in shares of Corbus Pharmaceuticals by 179.2% during the 4th quarter. Armistice Capital LLC now owns 536,000 shares of the biopharmaceutical company's stock worth $4,363,000 after purchasing an additional 344,000 shares during the period. Prosight Management LP boosted its position in shares of Corbus Pharmaceuticals by 99.1% during the 4th quarter. Prosight Management LP now owns 683,872 shares of the biopharmaceutical company's stock worth $5,567,000 after purchasing an additional 340,472 shares during the period. Finally, ADAR1 Capital Management LLC increased its holdings in Corbus Pharmaceuticals by 2,711.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 286,781 shares of the biopharmaceutical company's stock valued at $2,334,000 after purchasing an additional 276,581 shares during the last quarter. Institutional investors and hedge funds own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.